Omlyclo was originally approved in March 2025 in 2 single-dose prefilled syringe strengths: 75mg/0.5mL and 150mg/mL.
HealthDay News — In a practice guideline issued by the American Society for Radiation Oncology and published online November 17 in Practical Radiation Oncology, recommendations are presented for the ...
HealthDay News — A confidential internal memo from the US Food and Drug Administration (FDA) is creating new controversy around vaccine safety after an agency official said the COVID-19 vaccine may ...
HealthDay News — More than 69% of Medicaid enrollees with a new diagnosis of opioid use disorder (OUD) do not receive treatment within 180 days, according to a study published online November 23 in ...
Intensive behavioral therapy also recommended, including setting physical exercise and diet goals, energy intake restriction, weekly counseling.
ST-503 is a one-time dose, investigational epigenetic regulator that specifically targets and silences the SCN9A gene.
Zilganersen is an investigational antisense oligonucleotide designed to block the product of excess GFAP caused by mutations in the GFAP gene.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback